Free Trial

Novozymes A/S (OTCMKTS:NVZMY) Rating Lowered to Strong Sell at Zacks Research

Novozymes A/S logo with Basic Materials background
Image from MarketBeat Media, LLC.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued on Monday,Zacks.com reports.

Separately, Rothschild & Co Redburn raised Novozymes A/S to a "strong-buy" rating in a report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy".

View Our Latest Stock Report on Novozymes A/S

Novozymes A/S Stock Down 0.0%

Shares of Novozymes A/S stock opened at $62.32 on Monday. The company has a quick ratio of 0.44, a current ratio of 0.72 and a debt-to-equity ratio of 0.12. The firm has a market cap of $25.83 billion, a P/E ratio of 44.51, a P/E/G ratio of 1.17 and a beta of 0.98. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.99. The business has a 50-day moving average price of $58.29 and a 200 day moving average price of $61.15.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.31). Novozymes A/S had a net margin of 13.96% and a return on equity of 6.37%. On average, sell-side analysts forecast that Novozymes A/S will post 2.42 earnings per share for the current fiscal year.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company's product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novozymes A/S Right Now?

Before you consider Novozymes A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.

While Novozymes A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines